Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafael Rosell

Showing results (121-130 of 565) with videos related to

Pageof 57
Sort By:
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 25, 2006
From the bench to the bed: individualizing treatment in non-small-cell lung cancerMariacarmela Santarpia, Giuseppe Altavilla, Fernanda Salazar, et al.
Translational Lung Cancer Research|November 19, 2020
A narrative review of lung cancer cytology in the times of coronavirus: what physicians should knowPasquale Pisapia, Umberto Malapelle, Maria Salatiello, et al.
Journal of Thoracic Disease|July 10, 2020
Mechanisms of resistance to osimertinibChiara Lazzari, Vanesa Gregorc, Niki Karachaliou, et al.
Clinical Lung Cancer|June 15, 2007
Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapyCarlos Camps, Rafael Sirera, Vega Iranzo, et al.
Future Oncology (London, England)|April 21, 2009
IL-6/gp130/STAT3 signaling axis in cancer and the presence of in-frame gp130 somatic deletions in inflammatory hepatocellular tumorsRafael Rosell, Jordi Bertran-Alamillo, Miguel Angel Molina, et al.
Translational Lung Cancer Research|May 22, 2018
Osimertinib in untreated epidermal growth factor receptor (<i>EGFR</i>)-mutated advanced non-small cell lung cancerVanesa Gregorc, Chiara Lazzari, Niki Karachaliou, et al.
Frontiers in Oncology|October 5, 2020
Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancerRafael Rosell, Martyna Filipska, Imane Chaib, et al.
Drug News & Perspectives|December 25, 2010
Epigenetic alterations of tumor marker microRNAs: towards new cancer therapiesJia Wei, Li Xie, Miquel Taron, et al.
Pharmacogenomics|October 3, 2015
Pharmacogenomics in the treatment of lung cancer: an updateDaniela Morales-Espinosa, Silvia García-Román, Niki Karachaliou, et al.
Future Oncology (London, England)|June 6, 2007
Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitorsRafael Rosell, Miquel Taron, Jose Javier Sanchez, et al.
Pageof 57

Showing results (121-130 of 565) with videos related to

Sort By:
Pageof 57
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 25, 2006
From the bench to the bed: individualizing treatment in non-small-cell lung cancerMariacarmela Santarpia, Giuseppe Altavilla, Fernanda Salazar, et al.
Translational Lung Cancer Research|November 19, 2020
A narrative review of lung cancer cytology in the times of coronavirus: what physicians should knowPasquale Pisapia, Umberto Malapelle, Maria Salatiello, et al.
Journal of Thoracic Disease|July 10, 2020
Mechanisms of resistance to osimertinibChiara Lazzari, Vanesa Gregorc, Niki Karachaliou, et al.
Clinical Lung Cancer|June 15, 2007
Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapyCarlos Camps, Rafael Sirera, Vega Iranzo, et al.
Future Oncology (London, England)|April 21, 2009
IL-6/gp130/STAT3 signaling axis in cancer and the presence of in-frame gp130 somatic deletions in inflammatory hepatocellular tumorsRafael Rosell, Jordi Bertran-Alamillo, Miguel Angel Molina, et al.
Translational Lung Cancer Research|May 22, 2018
Osimertinib in untreated epidermal growth factor receptor (<i>EGFR</i>)-mutated advanced non-small cell lung cancerVanesa Gregorc, Chiara Lazzari, Niki Karachaliou, et al.
Frontiers in Oncology|October 5, 2020
Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancerRafael Rosell, Martyna Filipska, Imane Chaib, et al.
Drug News & Perspectives|December 25, 2010
Epigenetic alterations of tumor marker microRNAs: towards new cancer therapiesJia Wei, Li Xie, Miquel Taron, et al.
Pharmacogenomics|October 3, 2015
Pharmacogenomics in the treatment of lung cancer: an updateDaniela Morales-Espinosa, Silvia García-Román, Niki Karachaliou, et al.
Future Oncology (London, England)|June 6, 2007
Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitorsRafael Rosell, Miquel Taron, Jose Javier Sanchez, et al.
Pageof 57